SCHEMBL23294662

SCHEMBL23294662

O=C(O)c1[nH]nnc1-c1ccccc1F

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HAO1 Q9UJM8 9/20 0.42
▸ PKM P14618 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ ACMSD Q8TDX5 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ ALPL P05186 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ DCUN1D1 Q96GG9 1/20 0.37
▸ NOTUM Q6P988 1/20 0.37
▸ CSNK2A2 P19784 1/20 0.37
▸ CSNK2B P67870 1/20 0.37
▸ DHODH Q02127 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852207 1.00 HAO1 (0.42) HAO1PKMHPGDHTTPOLB
SCHEMBL17866354 0.82 HAO1 (0.40) HAO1HPGDRAB9AKDM4EALDH1A1
SCHEMBL31172948 0.82 HAO1 (0.40) HAO1HPGDRAB9AKDM4EALDH1A1
SCHEMBL23294571 0.81 HAO1 (0.41) HAO1HPGDNPC1RAB9AKDM4E
SCHEMBL23294634 0.79 KMO (0.46) HAO1ALPL
SCHEMBL15946998 0.78 KDM4E (0.46) HAO1HPGDPOLBNPC1RAB9A
Hydrochloric Acid SCHEMBL3527570 0.76 KDM4E (0.44) HAO1HPGDPOLBNPC1RAB9A
SCHEMBL23294375 0.75 MAP2K4 (0.45) HAO1HPGDPOLBRAB9AKDM4E
SCHEMBL23294477 0.75 MAP2K4 (0.45) HAO1HPGDPOLBRAB9AKDM4E
SCHEMBL14705874 0.73 HAO1 (0.49) HAO1ALDH1A1ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4051667-B1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS LILAC THERAPEUTICS INC (US) 2026-01-28 — — EP disclosed
US-20250064787-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors LILAC THERAPEUTICS INC (US) 2025-02-27 — — US disclosed
US-12168002-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2024-12-17 — — US disclosed
EP-4470538-A2 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
US-20240091200-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors Lilac Therapeutics, Inc. 2024-03-21 — — US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 — — US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 — — US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 — — US disclosed
EP-4051667-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. (US) 2022-09-07 — — EP disclosed
CN-114929676-A Heterocyclic carboxylate compounds as glycolate oxidase inhibitors 紫丁香疗法有限公司 2022-08-19 — — CN disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 — — US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 — — US disclosed
WO-2021086874-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS GyanRx Sciences, Inc. (US) 2021-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240091200-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors UGDH, PGD, PNPO HAO1 46/4885PKM 1567/4885HPGD 78/4885
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO HAO1 46/4885PKM 1567/4885HPGD 78/4885
US-12168002-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO HAO1 46/4885PKM 1567/4885HPGD 78/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO HAO1 46/4885PKM 1567/4885HPGD 78/4885
US-20250064787-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors GLS, DUOX1, HAO1 HAO1 3/4885PKM 1670/4885HPGD 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback